voltaren 140 mg lääkelaastari
haleon denmark aps - diclofenac sodium - lääkelaastari - 140 mg - diklofenaakki
cuvitru 200 mg/ml injektioneste, liuos
baxalta innovations gmbh - human normal immunoglobulin - injektioneste, liuos - 200 mg/ml - ihmisen normaali immunoglobuliini ekstravaskulaariseen käyttöön
dienorette 2,0 mg / 0,03 mg tabletti, kalvopäällysteinen
exeltis healthcare s.l. - dienogest, ethinylestradiol - tabletti, kalvopäällysteinen - 2,0 mg / 0,03 mg - dienogesti ja etinyyliestradioli
mavenclad
merck europe b.v. - kladribiini - multippeliskleroosi - immunosuppressantit - hoito aikuispotilailla, joilla on erittäin aktiivinen relapsoiva multippeliskleroosi (ms) kliinisten tai kuvantamisominaisuuksien perusteella.
fasenra
astrazeneca ab - benralizumab - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - fasenra on merkitty add huolto hoito aikuisilla potilailla, joilla on vaikea eosinofiilinen astma on riittävästi hallinnassa huolimatta korkea-annos inhaloitavat kortikosteroidit plus pitkävaikutteista β-agonistit.
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressantit - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.
prolutex 25 mg injektioneste, liuos
ibsa farmaceutici italia s.r.l - progesterone - injektioneste, liuos - 25 mg - progesteroni
perxine 50 mg/g emulsiovoide
infectopharm arzneimittel und consilium gmbh - permethrin - emulsiovoide - 50 mg/g - permetriini